^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:PMD-026 (pan-RSK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2022
    Title:

    5378 - PMD-026, a first in class oral RSK inhibitor, demonstrates activity against hormone receptor positive breast cancer with acquired CDK4/6 inhibitor resistance

    Published date:
    03/09/2022
    Excerpt:
    Here in we demonstrate that PMD-026 inhibits growth of HR+ BC cell lines MCF-7 and T47D in vitro...PMD-026 and fulvestrant combination is a potential alternative treatment for HR+ BC patients.
    Secondary therapy:
    fulvestrant